1cP-LSD

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-24srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-24srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
6. 2026-09-24srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
7. 2026-09-24srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
8. 2026-09-24srcReturn of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
9. 2026-09-24srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
10. 2026-09-24srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
11. 2026-09-24srcPharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration
12. 2026-09-24srcReturn of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)
13. 2026-09-24srcAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)
14. 2026-09-24srcA Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
15. 2026-09-24srcChemistry and Structure-Activity Relationships of Psychedelics.
16. 2026-09-24srcDesigner drugs: mechanism of action and adverse effects
17. 2026-09-24srcThe toxicity of psychedelic LSD derivatives: in silico approach for 1cP-LSD and analogs
18. 2026-09-24srcFlashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
19. 2026-09-24srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
20. 2026-09-24srcChronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.
21. 2026-09-24srcLysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
22. 2026-09-24srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
23. 2026-09-24srcStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
24. 2026-09-24src5-HT2A receptors: Pharmacology and functional selectivity
25. 2026-09-24srcMechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose?
26. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
27. 2026-09-24srcAcute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
28. 2026-09-24srcDose-response relationships of LSD-induced subjective experiences in humans
29. 2026-09-24srcAcute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants
30. 2026-09-24srcPharmacological and non-pharmacological predictors of the LSD experience in healthy participants
31. 2026-09-24srcPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
32. 2026-09-24srcPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
33. 2026-09-24srcIdentification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet
34. 2026-09-24srcPsychedelics and the human receptorome
35. 2026-09-24srcForensic Aspects of Designer LSD Analogs Identification by GC-MS (EI) and UV Spectroscopy
36. 2026-09-24srcEvaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention
37. 2026-09-24srcHallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
38. 2026-09-24srcLysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain
39. 2026-09-24src1cP-LSD Ban - The German NpSG 2021 revision
40. 2026-09-24src1cP-LSD - PsychonautWiki
41. 2026-09-04issueIssued emergency
42. 2026-09-04issueIssued info_card
43. 2026-09-04issueIssued notice
44. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
45. 2026-06-04publicationPublication — backfill
46. 2026-04-26revisionRevision 1
47. 2026-04-26absenceSearched Multiple for "Cross-referencing seed data against published sources" — no results
48. 2026-04-26absenceSearched ClinicalTrials.gov for "1cP-LSD lysergamide psychedelic" — no results
49. 2026-04-26absenceSearched ClinicalTrials.gov for "1cP-LSD lysergamide psychedelic" — no results
50. 2026-04-26genGeneration — pipeline-v5pipeline-v5
51. 2026-04-26rungeneration run

The same entries, as forms: six forms.